Bodewell Products for the Treatment of Atopic Dermatitis

NCT05566262 | Active Not Recruiting Phase 4 FDA Drug

• 2 other identifiers: IRB-300008755UAB
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to examine the safety and efficacy of topical application of the Bodewell eczema products

Conditions

Atopic Dermatitis

Outcome Measures

Primary Outcomes (1)

• Mean Percentage improvement in Patient Global Assessment (PGA)

  Mean percentage improvement in the Patient Global Assessment from baseline to week 12. This assessment is a scale from 0 to 4. 0 means clear skin while 4 means severe disease.

  Baseline to week 12

Secondary Outcomes (1)

• Percent improvement in Dermatology Life Quality Index (DLQI)

  Baseline to week 12

Study Arms (1)

Bodewell Treatment

EXPERIMENTAL

All patients will be treated with the active product, Bodewell. Bodewell will be applied topically twice a day to all active lesions.

Drug: Bodewell Calming Cream

Interventions

Bodewell Calming Cream DRUG

Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.

Bodewell Treatment

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• In good health (except for disease under study) as judged by the Investigator, based on medical history, physical examination, clinical laboratories, and urinalysis. (NOTE: The definition of good health means a subject does not have uncontrolled significant co- morbid conditions).
• years of age or older
• Able and willing to give written informed consent prior to any study procedures being conducted, and authorize the release and use of protected health information (PHI)
• Willing to have photos taken of their skin
• Diagnosis of chronic atopic dermatitis that has been present for at least 6 months prior to baseline
• Atopic dermatitis involving at least 3-10 % of the patient's body surface area
• Must have discontinued all systemic therapies for the treatment of atopic dermatitis at least 4 weeks or 5 half-lives, and biologics 6 months prior to baseline visit
• Must have discontinued all topical therapies for the treatment of atopic dermatitis at least 2 weeks prior to baseline visit
• Females of childbearing potential must use an approved birth control method while receiving treatment and for 28 days following the investigational product and there must be a documented negative pregnancy tests prior to initiating treatment. Approved birth control methods include hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring), intrauterine device, tubal ligation, partner vasectomy, or male or female condoms that are not made of natural materials PLUS a diaphragm with spermicide, cervical cap with spermicide, or a contraceptive sponge with spermicide.
• Females not of child bearing potential are defined as being at least 1 year postmenopausal or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy).
• patients must be on a stable dose of systemic therapy for the last 6 months prior to screening visit
• patients must be skin of color

You may not qualify if:

• Other than disease under study, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled
• Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study
• Prior history of suicide attempt at any time in the subject's life time prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years
• Pregnant or breast feeding
• Active substance abuse or a history of substance abuse within 6 months prior to Screening
• Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer)
• Prior treatment with the investigational product within 4 weeks prior to randomization
• Unable to comply with the protocol (as defined by the Investigator; i.e. drug or alcohol abuse or history of noncompliance)
• Any other dermatologic conditions that prohibit or confound the ability of the investigator to interpret skin findings.
• Patients who will be unable to avoid the use of systemic steroids, excluding intranasal or inhaled steroids that will be permitted, for the duration of the trial

Sponsors & Collaborators

• University of Alabama at Birmingham: lead
• Procter and Gamble: collaborator

Study Sites (1)

The University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States

Location

MeSH Terms

Conditions

Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Tiffany Mayo, MD

  University of Alabama at Birmingham

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: September 29, 2022
• First Posted: October 4, 2022
• Study Start: November 1, 2023
• Primary Completion (Estimated): February 1, 2027
• Study Completion (Estimated): February 1, 2028
• Last Updated: March 2, 2026

Record last verified: 2026-02

Locations

US (1)